pCMV-SPORT6 transient transfection

JD Jennifer K. Dowling
RA Remsha Afzal
LG Linden J. Gearing
MC Mariana P. Cervantes-Silva
SA Stephanie Annett
GD Gavin M. Davis
CS Chiara De Santi
NA Nadine Assmann
KD Katja Dettmer
DG Daniel J. Gough
GB Glenn R. Bantug
FH Fidinny I. Hamid
FN Frances K. Nally
CD Conor P. Duffy
AG Aoife L. Gorman
AL Alex M. Liddicoat
EL Ed C. Lavelle
CH Christoph Hess
PO Peter J. Oefner
DF David K. Finlay
GD Gavin P. Davey
TR Tracy Robson
AC Annie M. Curtis
PH Paul J. Hertzog
BW Bryan R. G. Williams
CM Claire E. McCoy
request Request a Protocol
ask Ask a question
Favorite

1.5 × 106 Raw-264.7 cells were seeded in a 6-well plate in complete DMEM and left overnight to propagate. The following day, fresh serum-free DMEM (without antibiotic) was added to the cells for transfection. Overexpression plasmids were purchased as pCMV-SPORT-6-Arg2 and pCMV-SPORT6-Arg1 (Invitrogen). They were transfected at 500 ng/well in the respective wells using Lipofectamine 3000 (Invitrogen). For control wells, an empty vector pCMV-SPORT6 plasmid was used. Cells were incubated at 37 °C and 5% CO2 for 4 h with the transfection mix in serum and antibiotic free media, after which media was replaced with complete DMEM. Cells were incubated for a further 24 h for Immunoblotting. For metabolic profiling assays, cells were scraped 24 hours post-transfection, counted for number and viability and transferred to XFe96-well plates (Agilent) for another 24 h before conducting the assay.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A